Wegovy HD (Semaglutide 7.2 mg): A Primary-Source Reference
Wegovy HD is the name commonly used for the 7.2 mg semaglutide strength that appears in Section 3 of the FDA-approved Wegovy prescribing information. This page records what the label states about that strength and about semaglutide's pharmacokinetics, and is explicit about the one thing it will not do: publish an escalation path to it. Reference material, not clinical guidance.
· Educational content — not medically reviewed
The short answer
Wegovy HD is the name commonly used for the 7.2 mg semaglutide strength the FDA-approved Wegovy prescribing information lists in Section 3, Dosage Forms and Strengths, via DailyMed. The pharmacokinetic statements in Section 12.3 belong to the molecule, not the strength: a half-life of approximately one week, 89% absolute bioavailability, and peak concentration one to three days post dose. How anyone reaches that strength is an escalation instruction, and it stays with the prescriber.
Key takeaways
- A 7.2 mg strength appears in Section 3, Dosage Forms and Strengths, of the Wegovy prescribing information (via DailyMed, accessed 1 September 2026), alongside the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg strengths.
- The pharmacokinetic statements in Section 12.3 are for semaglutide as a molecule: an elimination half-life of approximately 1 week, an absolute bioavailability of 89%, and maximum concentration 1 to 3 days post dose.
- A higher labeled strength does not change half-life, bioavailability or time to peak. Those are properties of the molecule, not of the strength on the box.
- This page does not publish how anybody reaches a 7.2 mg strength, over what interval, or from what starting point. That is an escalation instruction and it belongs to a prescriber.
- Not clinician-reviewed and not medical advice. It is a transcription of public labeling with the source named beside each figure.
7.2 mg is a labeled strength
Section 3, Dosage Forms and Strengths, of the Wegovy prescribing information lists a 7.2 mg strength (via DailyMed, accessed 1 September 2026). Naming a strength that exists in a public label is product identification. It is not a recommendation that anybody use it.
The pharmacokinetics do not change
Section 12.3 states an elimination half-life of approximately 1 week and an absolute bioavailability of 89% for semaglutide. These are molecular properties. They are the same figures the label gives for every semaglutide injection strength.
What the strength does change
A higher strength raises the amount of drug entering the system per dose, and therefore the level the system settles at. It does not make the molecule clear faster or slower, and it does not shorten the weeks it takes to reach a steady level.
No escalation path appears here
This page states that a stepwise schedule exists and that the label defines it. It does not reproduce the steps, the intervals, or the conditions for moving between strengths. That information is dosing guidance and this pillar does not publish dosing guidance.
What this page is, and what it is not
This is a reference page about a labeled product strength. Its job is to record, with attribution, what the FDA-approved United States prescribing information for Wegovy states, so that somebody encountering the term "Wegovy HD" can see what the underlying document actually says rather than what a forum post says it says.
It is not medical advice, it has not been reviewed by a clinician, and it makes no recommendation about whether any strength of any medication is appropriate for anybody. It is especially important to say that on this page, because a high-dose product is exactly the kind of subject where a reader might hope a web page will tell them something a prescriber has not. It will not, and it should not.
If you have a question about whether a particular strength is right for you, that is a conversation with your prescriber. There is no version of that conversation a reference page can substitute for.
GLP-1 Tracker visualizes your estimated medication level over time.
The primary source behind every number here
Every figure on this page comes from one document: WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use — the United States Prescribing Information approved by the FDA, read on DailyMed accessed 1 September 2026. The label records an Initial U.S. Approval of 2017.
Two sections are relevant. Section 3, Dosage Forms and Strengths, is where the available strengths are enumerated, and it is where the 7.2 mg strength appears. Section 12.3, Pharmacokinetics, is where the half-life, bioavailability and time-to-peak statements sit.
Note that "Wegovy HD" is not the label's own phrasing for a separate product. The current prescribing information covers semaglutide injection across its labeled strengths, including 7.2 mg, together with the oral tablet. Where this page uses the term it is describing the higher strength as it is commonly referred to, and every underlying figure is attributed to the label rather than to the nickname.
What the label lists under dosage forms and strengths
Section 3 of the prescribing information enumerates the injection strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg. The oral tablet strengths are listed separately as 1.5 mg, 4 mg, 9 mg and 25 mg.
It is worth being precise about what a list of strengths is and is not. It is an inventory of the presentations the FDA has approved for marketing. It is not a sequence, it is not a plan, and it carries no implication that any individual person progresses through all of it or ends anywhere in particular.
That distinction gets lost constantly in online discussion, where a list of strengths is read as a ladder everybody is expected to climb. The prescribing information's dosage and administration section is a separate section for a reason, and this page does not reproduce it.
Why a higher strength does not mean a different half-life
This is the most common misconception about high-dose presentations, and it is worth addressing directly because it has a clean answer.
Half-life, absolute bioavailability and time to peak are properties of the molecule and its route of administration. Section 12.3 states them for semaglutide: approximately 1 week, 89%, and 1 to 3 days post dose respectively. Those statements are not qualified by strength.
What a higher strength changes is the quantity entering the circulation with each dose, and therefore the concentration the body settles at once dosing is regular. It does not change the rate of clearance, and it does not change how many weeks it takes for levels to stop climbing. A person on a higher strength is not on a faster-moving medication. They are on the same medication at a different level.
The accumulation question, answered without a schedule
Because semaglutide's labeled half-life is approximately 1 week and the dosing interval is also weekly, each dose is given while a substantial proportion of the previous one is still present. Levels therefore climb across the first several doses before flattening.
That is a general property of any medication whose dosing interval is close to its half-life, and it is why the semaglutide labels describe steady state as arriving after several weeks of regular administration rather than immediately.
The practical consequence for record-keeping is the same one that appears throughout this pillar: an individual week is not an isolated event. If you are trying to describe to a clinician how a particular period felt, the useful record is a continuous one, because the thing you are describing was produced by several weeks acting together and not by one.
Why this page publishes no escalation path
There is a stepwise escalation described in the prescribing information's dosage and administration section, and this page will not reproduce it in any form — not as a list, not as prose, not as a range of intervals.
The reason is specific rather than generic. Escalation to a higher strength is precisely the decision where individualisation matters most: tolerability, other medications, clinical circumstances and how a person has responded so far all feed into it, and none of those are visible to a website. A page that publishes the steps is functionally handing a reader a plan they did not get from anybody qualified to give it.
So the framing stays where it belongs. A schedule exists. It is in the label. It is applied to you by your prescriber. A tracking app's role begins after that decision has been made, when there is something real to record.
What a tracking app can legitimately record
GLP-1 Tracker records what you enter and nothing else: the date of each dose you log, the strength as it was prescribed to you, the injection site you noted, weight entries over time, meals captured through the photo scan, and notes about how a week went.
That is a genuinely useful thing to have when a strength changes, because a change is exactly the moment when an accurate before-and-after record becomes worth something. Being able to say when a change happened, and what the weeks either side of it actually looked like, is far better than reconstructing it from memory at an appointment.
What the app does not do is evaluate any of it. It does not tell you whether a strength is working, it does not flag anything as clinically significant, and it does not suggest changes. It keeps the record; the interpretation belongs to your provider.
Bringing an accurate record to your prescriber
The practical reason to care about any of this is the appointment. Prescribers work from what you can tell them, and most people reconstructing several weeks from memory get exactly the details wrong that matter most — which week something started, whether a symptom preceded or followed a change, how weight actually moved rather than how it felt.
A log fixes that without needing to be clever. Dates, strengths as prescribed, sites, weights, notes. Accurate and boring beats interpreted and confident every time.
What you should not bring is a conclusion drawn from a reference page or an app chart. Bring the record and leave the interpretation to the person qualified to do it and who knows your history. That division of labour is the entire point of this pillar.
Frequently asked questions
What is Wegovy HD?
"Wegovy HD" is the term commonly used for the 7.2 mg semaglutide injection strength, which appears in Section 3, Dosage Forms and Strengths, of the FDA-approved Wegovy prescribing information alongside the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg strengths (via DailyMed, accessed 1 September 2026). Naming a labeled strength is product identification, not a recommendation that anybody use it.
Does Wegovy HD have a different half-life?
No. Section 12.3 of the prescribing information states an elimination half-life of approximately 1 week for semaglutide, and that statement is not qualified by strength. Half-life, bioavailability and time to peak are properties of the molecule and its route of administration rather than of the amount in a given presentation.
What does a higher strength actually change?
It changes the quantity of drug entering the circulation with each dose, and therefore the concentration the body settles at with regular dosing. It does not change how quickly the molecule is cleared, and it does not shorten the number of weeks levels take to stop climbing. A higher strength is the same medication at a different level, not a faster one.
How do you get to the 7.2 mg dose?
This page will not answer that, and the omission is deliberate. Escalation between strengths is described in the label's dosage and administration section and is individualised by a prescriber, taking account of tolerability, other medications and clinical circumstances that no website can see. If you want to know whether a change applies to you, that is a question for the person who prescribed your medication.
What is the bioavailability of semaglutide injection?
Section 12.3 states an absolute bioavailability of 89% following subcutaneous administration (via DailyMed, accessed 1 September 2026). The same figure applies across the labeled injection strengths, because bioavailability describes the fraction of an administered dose reaching systemic circulation rather than the size of the dose.
Has this page been reviewed by a doctor?
No. This is a reference page assembled from publicly available FDA-approved labeling, with the document, section and access date printed beside each figure so you can check any of it yourself. It has not been written or reviewed by a clinician, it is not medical advice, and it is not a substitute for professional care.
Record the strength you were prescribed, not the one you read about
GLP-1 Tracker logs the doses and strengths you were actually given, the sites you used, your weight trend and your meals, so a change is visible in your history instead of remembered. Educational and organizational only — never a substitute for your provider.
Reading on a desktop? Scan to open it on your iPhone.apps.apple.com/app/id6765520636
This page is for general education only and is not medical advice, diagnosis or treatment. GLP-1 Tracker is a tracking tool, not a medical device. Always consult your healthcare provider about your medication, dosing and health decisions. Brand names are trademarks of their respective owners and are not affiliated with this app.